Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954802 | 0.81 | ERN1 (0.37) | ERN1ALDH1A1 | |
| SCHEMBL746942 | 0.81 | NFE2L2 (0.41) | ERN1ALDH1A1TSHRPRKDCL3MBTL1 | |
| SCHEMBL28154686 | 0.81 | ERN1 (0.41) | ERN1ALDH1A1TSHRPRKDCFDPS | |
| SCHEMBL441518 | 0.81 | ERN1 (0.37) | ERN1ALDH1A1 | |
| SCHEMBL25230147 | 0.79 | ERN1 (0.36) | ERN1ALDH1A1KDM4E | |
| SCHEMBL31563047 | 0.79 | ERN1 (0.36) | ERN1ALDH1A1 | |
| SCHEMBL438652 | 0.79 | NFE2L2 (0.42) | ERN1ALDH1A1TDP1 | |
| SCHEMBL15335119 | 0.79 | ERN1 (0.40) | ERN1ALDH1A1TSHRPRKDCFDPS | |
| SCHEMBL16333419 | 0.79 | AURKA (0.40) | ERN1ALDH1A1IKBKBMAPK1 | |
| SCHEMBL772591 | 0.79 | ERN1 (0.46) | ERN1ALDH1A1PRKDCL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024032782-A1 | VACCINE ADJUVANTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO.LTD. (CN) | 2024-02-15 | — | — | WO | disclosed |
| EP-4313962-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| US-20230203214-A1 | AZACOUMARIN AND AZATHIOCOUMARIN DERIVATIVES FOR USE IN OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203214-A1 | AZACOUMARIN AND AZATHIOCOUMARIN DERIVATIVES FOR USE IN OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-06-29 | — | — | US | disclosed |
| WO-2023109942-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2021233800-A1 | AZACOUMARIN AND AZATHIOCOUMARIN DERIVATIVES FOR USE IN OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2021-11-25 | — | — | WO | disclosed |
| EP-3697763-A1 | D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | Syneurx International (Taiwan) Corp. (TW) | 2020-08-26 | — | — | EP | disclosed |
| WO-2019076329-A9 | D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | TSAI GUOCHUAN EMIL (CN) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019076329-A1 | D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | TSAI GUOCHUAN EMIL (CN) | 2019-04-25 | — | — | WO | disclosed |
| WO-2010131191-A1 | THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010131191-A1 | THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010131192-A2 | NOVEL OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010131192-A2 | NOVEL OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-18 | — | — | WO | disclosed |
| CN-101277939-A | Acyclic ikur inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-10-01 | — | — | CN | disclosed |
| EP-0659737-B1 | Catecholamine surrogates useful as beta 3 agonists | BRISTOL MYERS SQUIBB CO (US) | 2003-03-26 | — | — | EP | disclosed |
| US-5776983-A | ANTIDIABETIC AGENTS, OBESITY, GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| CN-1109050-A | Catecholamine surrogates useful as beta3 agonists | BRISTOL MYERS SQUIBB CO (US) | 1995-09-27 | — | — | CN | disclosed |
| EP-0659737-A2 | Catecholamine surrogates useful as B3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |
| EP-0462800-A2 | Inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | disclosed |